arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2016-22-5-432-440arthyper-473Research ArticleРЕДАКЦИОННАЯ СТАТЬЯEDITORIALАртериальная гипертензия и коморбидность: современное состояние проблемыArterial hypertension and comorbidity: state of the artЧесниковаА. И.ChesnikovaA. I.

доктор медицинских наук, профессор, профессор кафедры внутренних болезней № 1 ФГБОУ ВПО РостГМУ Минздрава России Тел.: +7(863)222–04–25

MD, PhD, DSc, Professor, Department of Internal Diseases № 1, Rostov State Medical University Phone: +7(863)222–04–25

rostov-ossn@yandex.ruБатюшинМ. М.BatyushinM. M.

доктор медицинских наук, профессор, профессор кафедры внутренних болезней № 2 ФГБОУ ВПО РостГМУ Минздрава России

MD, PhD, DSc, Professor, Department of Internal Diseases № 2, Rostov State Medical University

ТерентьевВ. П.TerentyevV. P.

доктор медицинских наук, профессор, заведующий кафедрой внутренних болезней № 1 ФГБОУ ВПО РостГМУ Минздрава России

MD, PhD, DSc, Professor, Head, Department of Internal Diseases № 1, Rostov State Medical University

Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Ростов‑на-Дону, Россия пер. Нахичеванский, д. 29, Ростов‑на-Дону, Россия, 344022.РоссияRostov State Medical University, Rostov-on-Don, Russia 29 Nakhichevansky avenue, Rostov-on-Don, Russia, 344022Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Ростов‑на-Дону, РоссияРоссияRostov State Medical University, Rostov-on-Don, RussiaRussian Federation201629112016225432440Copyright © Чесникова А.И., Батюшин М.М., Терентьев В.П., 20162016Чесникова А.И., Батюшин М.М., Терентьев В.П.Chesnikova A.I., Batyushin M.M., Terentyev V.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/473

Отличительной особенностью артериальной гипертензии (АГ) является высокая частота коморбидности. Пациенты с АГ, как правило, имеют одну или несколько сопутствующих патологий. К наиболее часто встречающимся относятся: сахарный диабет, метаболический синдром, хроническая болезнь почек, хроническая обструктивная болезнь легких, цереброваскулярная болезнь и другие. Коморбидность приводит к взаимному влиянию на течение заболеваний, характер и тяжесть осложнений, нередко затрудняет диагностику, определяет особенности выбора антигипертензивных препаратов. В рекомендациях Европейского общества кардиологов и Европейского общества по артериальной гипертензии, Американской ассоциации сердца и Американской Ассоциации инсультов, Российского кардиологического общества и Научного общества нефрологов России, Российского медицинского общества по артериальной гипертонии обозначены подходы к тактике ведения пациентов с АГ и сопутствующей патологией, основанные на данных доказательной медицины. Наличие коморбидности у больных АГ определяет не только выбор антигипертензивных препаратов, но и целевые значения артериального давления. В последнее время имеющиеся представления дополнены результатами новых исследований и метаанализов. Пациенты с АГ и коморбидностью требуют индивидуального подхода, комплексной диагностики и лечения с учетом всех имеющихся патологий.

Arterial hypertension (HTN) is frequently associated with comorbid diseases. Hypertensive patients commonly have one or several co-existent pathologies. The most frequent ones include diabetes mellitus, metabolic syndrome, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular disease and others. The comorbidities have mutual impact on each other, character and severity of complications. They often lead to complications, influence the choice of antihypertensive drugs. The guidelines of the European Society of Cardiologists and the European Society on Hypertension, the American Association of Heart and the American Association of Strokes, the Russian Cardiologic Society and Scientific Association of Nephrologists of Russia, the Russian Medical Society on Arterial Hypertension give recommendations based on the available evidence. Comorbidities influence both the choice of antihypertensive drugs and target blood pressure level. Recently the current concepts were updated by the novel results and meta-analyses. Hypertensive patients with coexistent pathologies require individual approach, complex diagnostics and treatment dependent on the type of comorbidity.

артериальная гипертензияантигипертензивная терапиякоморбидностьхроническая болезнь почекхроническая обструктивная болезнь легкихсахарный диабетцереброваскулярная болезньarterial hypertensionantihypertensive therapycomorbiditychronic kidney diseasechronic obstructive pulmonary diseasediabetes mellituscerebrovascular diseaseReferencesAlmagro P, Cabrera FJ, Diez J. Comorbidities and shortterm prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest. 2012;142(5):1126– 1133.Almagro P, Cabrera FJ, Diez J. Comorbidities and shortterm prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest. 2012;142(5):1126– 1133.Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fith Korean National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis. 2015;10:1571–1582.Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fith Korean National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis. 2015;10:1571–1582.Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2229– 2236.Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2229– 2236.Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525–9.Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525–9.Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke — a retrospective analysis. BMC Neurol. 2015;15:164.Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke — a retrospective analysis. BMC Neurol. 2015;15:164.Portegies ML, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am J Respir Crit Care Med. 2016;193(3):251–8. doi: 10.1164/rccm.201505–0962OC.Portegies ML, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am J Respir Crit Care Med. 2016;193(3):251–8. doi: 10.1164/rccm.201505–0962OC.Крючкова О. Н., Турна Э. Ю., Мартынюк М. А. Артериальная гипертензия у больных ХОБЛ: патогенетические особенности и суточная динамика артериального давления. Крымский терапевтический журнал. 2015;2:5–9. [Kryuchkova ON, Turna EY, Martynyuk MA. Arterial hypertension in GOLD: Pathogenetic features and daily dynamics of blood pressure. Krymsky Terapevticheskiy Zhurnal = Crimean Therapeutic Journal. 2015;2:5–9. In Russian].Крючкова О. Н., Турна Э. Ю., Мартынюк М. А. Артериальная гипертензия у больных ХОБЛ: патогенетические особенности и суточная динамика артериального давления. Крымский терапевтический журнал. 2015;2:5–9. [Kryuchkova ON, Turna EY, Martynyuk MA. Arterial hypertension in GOLD: Pathogenetic features and daily dynamics of blood pressure. Krymsky Terapevticheskiy Zhurnal = Crimean Therapeutic Journal. 2015;2:5–9. In Russian].Кароли Н. А., Долишняя Г. Р., Ребров А. П. Суточные показатели артериальной ригидности у мужчин с различными фенотипами хронической обструктивной болезни легких в сочетании с артериальной гипертензией. Клиницист. 2015;1:37– 41. [Karoly NA, Dolishnyaya GR, Rebrov AP. Daily indicators of arterial stiffness in men with various phenotypes of chronic obstructive pulmonary disease in combination with arterial hypertension. Klinitsist = Physician. 2015;1:37–41. In Russian].Кароли Н. А., Долишняя Г. Р., Ребров А. П. Суточные показатели артериальной ригидности у мужчин с различными фенотипами хронической обструктивной болезни легких в сочетании с артериальной гипертензией. Клиницист. 2015;1:37– 41. [Karoly NA, Dolishnyaya GR, Rebrov AP. Daily indicators of arterial stiffness in men with various phenotypes of chronic obstructive pulmonary disease in combination with arterial hypertension. Klinitsist = Physician. 2015;1:37–41. In Russian].Гуревич М. А., Долгова Е. В., Кузьменко Н. А. Хронические обструктивные заболевания легких, артериальная гипертензия и ишемическая болезнь сердца: особенности патогенеза, клинической картины, терапии. РМЖ. 2016;16:1098–1102. [Gurevich MA, Dolgova EV, Kuzmenko NA. Chronic obstructive diseases of lungs, arterial hypertension and coronary heart disease: features of a pathogenesis, clinical picture, therapy. Russian Medical Journal. 2016;16:1098–1102. In Russian].Гуревич М. А., Долгова Е. В., Кузьменко Н. А. Хронические обструктивные заболевания легких, артериальная гипертензия и ишемическая болезнь сердца: особенности патогенеза, клинической картины, терапии. РМЖ. 2016;16:1098–1102. [Gurevich MA, Dolgova EV, Kuzmenko NA. Chronic obstructive diseases of lungs, arterial hypertension and coronary heart disease: features of a pathogenesis, clinical picture, therapy. Russian Medical Journal. 2016;16:1098–1102. In Russian].Чазова И. Е., Чучалин А. Г., Зыков К. А., Ратова Л. Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013;1:5–34. [Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5–34. In Russian].Чазова И. Е., Чучалин А. Г., Зыков К. А., Ратова Л. Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013;1:5–34. [Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5–34. In Russian].Григорьева Н. Ю. Коморбидный пациент с АГ и ХОБЛ. Лечащий врач. 2016;7:54–58. [Grigorieva NY. The comorbid patient with arterial hypertension and COPD. Physician. 2016;7:54–58. In Russian].Григорьева Н. Ю. Коморбидный пациент с АГ и ХОБЛ. Лечащий врач. 2016;7:54–58. [Grigorieva NY. The comorbid patient with arterial hypertension and COPD. Physician. 2016;7:54–58. In Russian].Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.ONTARGET Investigators, Yusuf S, Teo KK, Pogue J,Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.ONTARGET Investigators, Yusuf S, Teo KK, Pogue J,Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229–40.Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229–40.Chandratilleke MG, Carson KV, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev. 2012;5: CD001116. doi: 10.1002/14651858.CD001116.pub3Chandratilleke MG, Carson KV, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev. 2012;5: CD001116. doi: 10.1002/14651858.CD001116.pub3Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,Cushman M et al. Heart disease and stroke statistics‑2015 update: a report from the American Heart Association. Circulation. 2015;131(4):29–322.Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,Cushman M et al. Heart disease and stroke statistics‑2015 update: a report from the American Heart Association. Circulation. 2015;131(4):29–322.Фонякин А. В., Гераскина Л. А. Артериальная гипертония и оптимизация медикаментозной профилактики ишемического инсульта. Кардиология. 2016;2(56):73–78. [Fonyakin AV, Geraskina LA. Arterial hypertonia and optimization of medicamental prophylaxis of an ischemic stroke. Kardiologiia. 2016;2(56):73–78. In Russian].Фонякин А. В., Гераскина Л. А. Артериальная гипертония и оптимизация медикаментозной профилактики ишемического инсульта. Кардиология. 2016;2(56):73–78. [Fonyakin AV, Geraskina LA. Arterial hypertonia and optimization of medicamental prophylaxis of an ischemic stroke. Kardiologiia. 2016;2(56):73–78. In Russian].Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et al. Guidelines for the primary prevention of stroke. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–3832.Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et al. Guidelines for the primary prevention of stroke. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–3832.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. Eur Heart J. 2013;34 (28):2159–2219.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. Eur Heart J. 2013;34 (28):2159–2219.Parsons C, Murad MH, Andersen S, Mookadam F, Labonte H. The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol. 2016;12(2):237–48.Parsons C, Murad MH, Andersen S, Mookadam F, Labonte H. The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol. 2016;12(2):237–48.Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and metaanalyses of randomized trials. J Hypertens. 2016;34(4):613–22.Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and metaanalyses of randomized trials. J Hypertens. 2016;34(4):613–22.Akioyamen L, Levine M, Sherifali D, O’Reilly D, Frankfurter C, Pullenayegum E et al. Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. J Am Soc Hypertens. 2016;10(1):55–69.Akioyamen L, Levine M, Sherifali D, O’Reilly D, Frankfurter C, Pullenayegum E et al. Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. J Am Soc Hypertens. 2016;10(1):55–69.Коростовцева Л. С., Звартау Н. Э., Баранцевич Е. Р., Конради А. О. Выбор антигипертензивного препарата в особых группах пациентов: данные доказательной медицины при сопутствующих заболеваниях нервной системы (часть 5). Артериальная гипертензия. 2015;21(2):116–120. [Korostovtseva LS, Zvartau NE, Barantsevich ER, Konradi AO. The choice of antihypertensive drug in special conditions: evidence-based data in co-morbid neurology diseases (part 5). Arterial’naya Gipertenziya = Arterial Hypertension. 2015;21(2):116–120. In Russian].Коростовцева Л. С., Звартау Н. Э., Баранцевич Е. Р., Конради А. О. Выбор антигипертензивного препарата в особых группах пациентов: данные доказательной медицины при сопутствующих заболеваниях нервной системы (часть 5). Артериальная гипертензия. 2015;21(2):116–120. [Korostovtseva LS, Zvartau NE, Barantsevich ER, Konradi AO. The choice of antihypertensive drug in special conditions: evidence-based data in co-morbid neurology diseases (part 5). Arterial’naya Gipertenziya = Arterial Hypertension. 2015;21(2):116–120. In Russian].Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45 (7):2160–2236.Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45 (7):2160–2236.Liu S, Li C, Li T, Xiong J, Zhao X. Effects of early hypertension control after ischaemic stroke on the outcome: a meta-analysis. Cerebrovasc Dis. 2015;40(5–6):270–8. doi: 10.1159/000441097.Liu S, Li C, Li T, Xiong J, Zhao X. Effects of early hypertension control after ischaemic stroke on the outcome: a meta-analysis. Cerebrovasc Dis. 2015;40(5–6):270–8. doi: 10.1159/000441097.Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2016. pii: HYPERTENSION AHA.116.08485.Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2016. pii: HYPERTENSION AHA.116.08485.Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane database of systematic reviews. 2015;1: CD008170.Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane database of systematic reviews. 2015;1: CD008170.Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM et al. Comparative effectiveness of blood pressurelowering drugs in patients who have already suffered from stroke: traditional and bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95(15):3302.Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM et al. Comparative effectiveness of blood pressurelowering drugs in patients who have already suffered from stroke: traditional and bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95(15):3302.Jeffers BW, Robbins J, Bhambri R. Efficacy of calcium channel blockers versus other classes of antihypertensive medication in the treatment of hypertensive patients with previous stroke and/or coronary artery disease: a systematic review and meta-analysis. Am J Therap. 2015;17(3):193–199. doi: 10.1111/jch.12462Jeffers BW, Robbins J, Bhambri R. Efficacy of calcium channel blockers versus other classes of antihypertensive medication in the treatment of hypertensive patients with previous stroke and/or coronary artery disease: a systematic review and meta-analysis. Am J Therap. 2015;17(3):193–199. doi: 10.1111/jch.12462Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia and other dementias. J Alzheimers Dis. 2011;26(4):699–708.Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia and other dementias. J Alzheimers Dis. 2011;26(4):699–708.Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, metaanalysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027–35.Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, metaanalysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027–35.Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. 2016. pii: gfw354. PMID:27738231. doi:10.1093/ndt/gfw354.Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. 2016. pii: gfw354. PMID:27738231. doi:10.1093/ndt/gfw354.Hong JW, Noh JH, Kim DJ. factors associated with high sodium intake based on estimated 24‑hour urinary sodium excretion: the 2009–2011 Korea National Health and Nutrition Examination Survey. Medicine (Baltimore). 2016;95(9):2864. doi:10.1097/MD.0000000000002864.Hong JW, Noh JH, Kim DJ. factors associated with high sodium intake based on estimated 24‑hour urinary sodium excretion: the 2009–2011 Korea National Health and Nutrition Examination Survey. Medicine (Baltimore). 2016;95(9):2864. doi:10.1097/MD.0000000000002864.Acuña L, Sánchez P, Soler LA, Alvis LF. Kidney disease in Colombia: priority for risk management. Rev Panam Salud Publica. 2016;40(1):16–22. PMID:27706391.Acuña L, Sánchez P, Soler LA, Alvis LF. Kidney disease in Colombia: priority for risk management. Rev Panam Salud Publica. 2016;40(1):16–22. PMID:27706391.Sim JJ, Bhandari SK, Shi J. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099– 107.Sim JJ, Bhandari SK, Shi J. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099– 107.Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ,Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ,Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.Holmqvist L, Boström KB, Kahan T, Schiöler L, Hasselström J, Hjerpe P et al. Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database. J Am Soc Hypertens. 2016. pii: S1933– 1711(16)30491–0. doi: 10.1016/j.jash.2016.08.008.Holmqvist L, Boström KB, Kahan T, Schiöler L, Hasselström J, Hjerpe P et al. Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database. J Am Soc Hypertens. 2016. pii: S1933– 1711(16)30491–0. doi: 10.1016/j.jash.2016.08.008.Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68(1):293–301.Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68(1):293–301.Терентьев В. П., Кобзева Н. Д., Батюшин М. М., Малеванный М. В. Особенности атеросклеротического поражения почечных артерий у больных острым коронарным синдромом. Нефрология. 2015;5:86–90. [Terentyev VP, Kobzeva ND, Batyushin MM, Malevanny MV. Features of an atherosclerotic lesion of renal arteries at patients with an acute coronary syndrome. Nephrology. 2015;5:86–90. In Russian].Терентьев В. П., Кобзева Н. Д., Батюшин М. М., Малеванный М. В. Особенности атеросклеротического поражения почечных артерий у больных острым коронарным синдромом. Нефрология. 2015;5:86–90. [Terentyev VP, Kobzeva ND, Batyushin MM, Malevanny MV. Features of an atherosclerotic lesion of renal arteries at patients with an acute coronary syndrome. Nephrology. 2015;5:86–90. In Russian].Zanoli L, Rastelli S, Marcantoni C, Capodanno D, Blanco J, Tamburino C et al. Non- hemodynamically significant renal artery stenosis predicts cardiovascular events in persons with ischemic heart disease. Am J Nephrol. 2014;40(5):468–77.Zanoli L, Rastelli S, Marcantoni C, Capodanno D, Blanco J, Tamburino C et al. Non- hemodynamically significant renal artery stenosis predicts cardiovascular events in persons with ischemic heart disease. Am J Nephrol. 2014;40(5):468–77.Trautmann A, Roebuck DJ, McLaren CA, Brennan E, Marks SD, Tullus K. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol. 2016. doi: 10.1007/s00467–016–3501–7Trautmann A, Roebuck DJ, McLaren CA, Brennan E, Marks SD, Tullus K. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol. 2016. doi: 10.1007/s00467–016–3501–7Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13–22.Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13–22.Yang YK, Zhang Y, Meng X, Yang KQ, Jiang XJ, Wu HY et al. Clinical characteristics and treatment of renal artery fibromuscular dysplasia with percutaneous transluminal angioplasty: a long-term follow-up study. Clin Res Cardiol. 2016;105(11):930–937.Yang YK, Zhang Y, Meng X, Yang KQ, Jiang XJ, Wu HY et al. Clinical characteristics and treatment of renal artery fibromuscular dysplasia with percutaneous transluminal angioplasty: a long-term follow-up study. Clin Res Cardiol. 2016;105(11):930–937.Rosa J, Widimský P, Waldauf Р, Lambert L, Zelinka T, Táborský M et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE‑15 study. Hypertension. 2016;67(2):397– 403. doi: 10.1161/HYPERTENSIONAHA.115.06526.Rosa J, Widimský P, Waldauf Р, Lambert L, Zelinka T, Táborský M et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE‑15 study. Hypertension. 2016;67(2):397– 403. doi: 10.1161/HYPERTENSIONAHA.115.06526.Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393– 1401.Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393– 1401.Hsu Ch-Ch, Wang H, Hsu Y‑H, Chuang SY, Huang YW, Chang YK et al. Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015;66 (3):524–33. doi: 10.1161/HYPERTENSIONAHA.114.05105.Hsu Ch-Ch, Wang H, Hsu Y‑H, Chuang SY, Huang YW, Chang YK et al. Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015;66 (3):524–33. doi: 10.1161/HYPERTENSIONAHA.114.05105.Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta- analysis of observational studies. Eur J Intern Med. 2015;26(4):285–91. doi: 10.1016/j.ejim.2015.03.008.Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta- analysis of observational studies. Eur J Intern Med. 2015;26(4):285–91. doi: 10.1016/j.ejim.2015.03.008.Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио- нефропротекции. Клинические рекомендации. РКО, НОНР, РАЭ, РМОАГ, НОА, РНМОТ. Российский кардиологический журнал. 2014;8(112):7–37. [Cardiovascular risk and chronic kidney disease: strategy of a cardionephroprotection. Clinical Guideline. RKO, NONR, RAE, RMOAH, RNMOT. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Cardiology Journal. 2014;8(112):7–37. In Russian].Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио- нефропротекции. Клинические рекомендации. РКО, НОНР, РАЭ, РМОАГ, НОА, РНМОТ. Российский кардиологический журнал. 2014;8(112):7–37. [Cardiovascular risk and chronic kidney disease: strategy of a cardionephroprotection. Clinical Guideline. RKO, NONR, RAE, RMOAH, RNMOT. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Cardiology Journal. 2014;8(112):7–37. In Russian].KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kibney Int. Suppl. volume 2, issue 5, 2012.KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kibney Int. Suppl. volume 2, issue 5, 2012.Kushiro T, Kario K, Saito I, Teramukai S, Sato Y, Okuda Y et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study. Hypertens Res. 2016. doi: 10.1038/hr.2016.87.Kushiro T, Kario K, Saito I, Teramukai S, Sato Y, Okuda Y et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study. Hypertens Res. 2016. doi: 10.1038/hr.2016.87.Ntaios G, Vemmos K, Lip GY, Koroboki E, Manios E, Vemmou A et al. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke. 2016;47(9):2278–85. doi: 10.1161/STROKEAHA.116.013713.Ntaios G, Vemmos K, Lip GY, Koroboki E, Manios E, Vemmou A et al. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke. 2016;47(9):2278–85. doi: 10.1161/STROKEAHA.116.013713.Батюшин М. М. Проспективное исследование влияния порога вкусовой чувствительности к поваренной соли на сердечно-сосудистые осложнения. Российский кардиологический журнал. 2015;9:19–24. [Batyushin MM. A prospective research of influence of a threshold of flavoring sensitivity to table salt on cardiovascular complications. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Cardiology Journal. 2015;9: 19–24. In Russian].Батюшин М. М. Проспективное исследование влияния порога вкусовой чувствительности к поваренной соли на сердечно-сосудистые осложнения. Российский кардиологический журнал. 2015;9:19–24. [Batyushin MM. A prospective research of influence of a threshold of flavoring sensitivity to table salt on cardiovascular complications. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Cardiology Journal. 2015;9: 19–24. In Russian].Fatema K, Zwar NA, Milton AH, Ali L, Rahman B. Prevalence of risk factors for cardiovascular diseases in bangladesh: a systematic review and meta-analysis. PloS one. 2016;11(8): e0160180. doi: 10.1371/journal.pone.0160180.Fatema K, Zwar NA, Milton AH, Ali L, Rahman B. Prevalence of risk factors for cardiovascular diseases in bangladesh: a systematic review and meta-analysis. PloS one. 2016;11(8): e0160180. doi: 10.1371/journal.pone.0160180.Halimi JM, Joly D, Combe C, Choukroun G, Dussol B, Fauvel JP et al. Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICEPROTECT study. BMC Nephrol. 2016;17(1):135. doi:10.1186/s12882–016–0336–1.Halimi JM, Joly D, Combe C, Choukroun G, Dussol B, Fauvel JP et al. Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICEPROTECT study. BMC Nephrol. 2016;17(1):135. doi:10.1186/s12882–016–0336–1.Derakhshan A, Bagherzadeh-Khiabani F, Arshi B, Ramezankhani A, Azizi F, Hadaegh F. Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. J Am Heart Assoc. 2016;5 (8). pii: e003917. doi: 10.1161/JAHA.116.003917.Derakhshan A, Bagherzadeh-Khiabani F, Arshi B, Ramezankhani A, Azizi F, Hadaegh F. Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. J Am Heart Assoc. 2016;5 (8). pii: e003917. doi: 10.1161/JAHA.116.003917.Standards of medical care in diabetes — 2016. Diabetes Care. 2016;39:119.Standards of medical care in diabetes — 2016. Diabetes Care. 2016;39:119.

The authors declare that there are no conflicts of interest present.